DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prolixin (Fluphenazine Decanoate) - Summary

 
 



PROLIXIN SUMMARY

PROLIXIN® ORAL CONCENTRATE
Fluphenazine Hydrochloride Oral Solution USP

Prolixin Decanoate is the decanoate ester of a trifluoromethyl phenothiazine derivative. It is a highly potent behavior modifier with a markedly extended duration of effect. Prolixin Decanoate is available for intramuscular or subcutaneous administration, providing 25 mg fluphenazine decanoate per mL in a sesame oil vehicle with 1.2% (w/v) benzyl alcohol as a preservative. At the time of manufacture, the air in the vials is replaced by nitrogen.

PROLIXIN (fluphenazine) is indicated for the following:

Prolixin Decanoate (Fluphenazine Decanoate Injection) is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics).

Prolixin Decanoate has not been shown effective in the management of behavioral complications in patients with mental retardation.


See all Prolixin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Prolixin (Fluphenazine)

First-Episode Psychosis Treatment: Lots of Room for Improvement
Source: Medscape Psychiatry & Mental Health Headlines [2014.12.09]
Almost two fifths of first-episode schizophrenia patients are not prescribed medications in line with current guideline recommendations.
Medscape Medical News

Medications for patients with first episode psychosis may not meet guidelines
Source: Depression News From Medical News Today [2014.12.08]
Many patients with first-episode psychosis receive medications that do not comply with recommended guidelines for first-episode treatment, researchers have found.

Findings presented at the Society for Neuroscience meeting by Johns Hopkins scientists
Source: Autism News From Medical News Today [2014.11.24]
A Blood Pressure Hormone Implicated in PsychosisIn an effort to find a marker that predicts psychosis, postdoctoral researcher Lindsay Hayes, Ph.D.

Could a blood test predict schizophrenia risk?
Source: Schizophrenia News From Medical News Today [2014.09.23]
A new study suggests a blood test could predict which patients are at risk of developing schizophrenia and other forms of psychosis, meaning they could receive earlier treatment.

more news >>

Published Studies Related to Prolixin (Fluphenazine)

The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. [2007.03.30]
Pharmacotherapy of schizophrenia is associated with the stressful side effects...

A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. [2006.04]
Sexual dysfunction is common in people suffering from schizophrenia and is reported by patients to be a significant reason for medication nonadherence. This report contains data for 27 people with schizophrenia who participated in a randomized double-blind 12-week trial of risperidone (4 mg/day), quetiapine (400 mg/day) or fluphenazine (12.5 mg/day)...

Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. [2005.07]
This 12-week, double-blind study evaluated the effectiveness of risperidone (4 mg/day), quetiapine (400 mg/day), or fluphenazine (12.5 mg/day) in a stringently defined treatment-resistant population of people with schizophrenia. No differences were noted in total Brief Psychiatric Rating Scale (BPRS) or Clinical Global Impression scores among the drug groups (n = 38)...

Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. [2005.01]
CONCLUSIONS: It is expected that TT(4) levels will decrease during quetiapine treatment, and this may possibly be related to competitive metabolism of thyroid hormones and quetiapine by UDP-glucuronosyltransferase. Routine monitoring of thyroid function in quetiapine-treated patients without a history of thyroid disease is not recommended.

Fluphenazine (oral) versus placebo for schizophrenia. [2013]
CONCLUSIONS: The findings in this review confirm much that clinicians

more studies >>

Clinical Trials Related to Prolixin (Fluphenazine)

Fluphenazine Hydrochloride for Psoriasis [Recruiting]
The objective of this study is to assess the safety and biologic activity of intralesional injection of fluphenazine in adult subjects with psoriasis.

Fluphenazine Decanoate for Psoriasis [Terminated]
We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U. S. Food and Drug Administration) approved for use in people who have schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test tubes. Its usefulness and safety in people with psoriasis will be investigated in this study.

Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma [Completed]
RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase I/II trial is studying the side effects and best dose of fluphenazine and to see how well it works in treating patients with refractory advanced multiple myeloma.

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia [Active, not recruiting]
The purpose of this study is to:

1. Evaluate the efficacy and safety of the new antipsychotics, quetiapine (300-500mg/day) and risperidone (3-4mg/day) compared to each other and to fluphenazine (10-15mg/day), a high potency typical antipsychotic in patients who meet the DSM IV criteria for schizophrenia.

2. To evaluate the efficacy and safety of quetiapine (1200mg/day) in patients who have not responded to conventional and newer antipsychotics.

3. To evaluate the effectiveness of quetiapine (300-500mg/day), and risperidone (3-5mg/day) compared to each other and fluphenazine (10-15mg/day) in the treatment of hostility and aggression in treatment-resistant schizophrenic patients.

4. To evaluate the effectiveness of quetiapine (300-500mg/day) and risperidone (3-5mg/day) compared to each other and fluphenazine (10-15mg/day) on rates of discharge, quality of life, and independent living skills.

5. To assess prolactin levels and to evaluate any relationship with sexual dysfunction and menstrual irregularities.

6. To evaluate the possible differential impact of treatment conditions on cognitive functioning including measures of attention, motor speed, problem solving, verbal and visual memory, and verbal processing speed.

7. To measure changes in weight and health consequences associated with weight changes.

A Comparison of Long-acting Injectable Medications for Schizophrenia [Recruiting]
The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).

more trials >>

Reports of Suspected Prolixin (Fluphenazine) Side Effects

Delusion (3)Neuroleptic Malignant Syndrome (3)Hypersensitivity (2)Drug Interaction (2)Cardiac Disorder (2)Brain Injury (2)Weight Increased (2)Overdose (2)Myocardial Infarction (2)Tardive Dyskinesia (2)more >>


Page last updated: 2014-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014